Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

Cancer

Volumn 113, Issue 2, 2008, Pages 355-359

  Barlogie, Bart ^a   Anaissie, Elias ^a   Haessler, Jeffrey ^b   Van Rhee, Fritz ^a   Pineda Roman, Mauricio ^a   Hollmig, Klaus ^a   Alsayed, Yazan ^a   Epstein, Joshua ^a   Shaughnessy Jr , John D ^a   Crowley, John ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Complete remission; Myeloma; Prognosis

Indexed keywords

IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CREATININE BLOOD LEVEL; CYTOGENETICS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; METAPHASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

AGED; HUMANS; MULTIPLE MYELOMA; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 48249127515     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23546     Document Type: Article

References (21)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2: 822-824.
2. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869-872.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
4. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89: 789-793.
5. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
6. Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol. 2007;136:393-399.
7. Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007;13:7073-7079.
8. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
9. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
10. Shaughnessy JD Jr, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007;137:530-536.
11. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958;53:457-481.
14. Cox DR. Regression tables and life tables. J Roy Stat Soc. 1972;B34:187-202.
15. Richardson P. Toward a new therapeutic backbone in myeloma. Blood. 2007;109:2672-2673.
16. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
17. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165-2172.
18. Palumbo A, Falco P, Benevolo G, et al. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma [abstract]. ASCO Meet Abstr. 2006. Abstract 7518.
19. Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial [abstract]. Blood. 2005;106:363.
20. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767-2772.
21. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827-832.